Codexis (CDXS) Competitors

Codexis (NASDAQ:CDXS) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking.

Do analysts rate CDXS or MYGN?

Codexis currently has a consensus target price of $8.00, suggesting a potential upside of 220.00%. Myriad Genetics has a consensus target price of $16.04, suggesting a potential upside of 294.97%. Given Myriad Genetics' higher possible upside, analysts plainly believe Myriad Genetics is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Myriad Genetics	3 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.12

Does the MarketBeat Community believe in CDXS or MYGN?

Myriad Genetics received 129 more outperform votes than Codexis when rated by MarketBeat users. However, 61.47% of users gave Codexis an outperform vote while only 52.69% of users gave Myriad Genetics an outperform vote.

Company	Underperform	Outperform
Codexis	Outperform Votes 351 61.47%	Underperform Votes 220 38.53%
Myriad Genetics	Outperform Votes 480 52.69%	Underperform Votes 431 47.31%

Is CDXS or MYGN more profitable?

Myriad Genetics has a net margin of -14.09% compared to Codexis' net margin of -96.35%. Myriad Genetics' return on equity of -4.51% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-96.35%	-71.56%	-38.00%
Myriad Genetics	-14.09%	-4.51%	-3.07%

Does the media favor CDXS or MYGN?

In the previous week, Myriad Genetics had 14 more articles in the media than Codexis. MarketBeat recorded 18 mentions for Myriad Genetics and 4 mentions for Codexis. Codexis' average media sentiment score of 1.25 beat Myriad Genetics' score of 0.12 indicating that Codexis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals believe in CDXS or MYGN?

78.5% of Codexis shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 2.1% of Codexis shares are held by company insiders. Comparatively, 2.4% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has better earnings & valuation, CDXS or MYGN?

Codexis has higher earnings, but lower revenue than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$59.35M	3.49	-$76.24M	-$0.90	-2.78
Myriad Genetics	$837.60M	0.45	-$263.30M	-$1.12	-3.63

Which has more risk & volatility, CDXS or MYGN?

Codexis has a beta of 2.56, meaning that its share price is 156% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.

Summary

Myriad Genetics beats Codexis on 10 of the 18 factors compared between the two stocks.